Supreme Court Hears Wyeth v. Levine Drug Pre-Emption Case
This article was originally published in The Gray Sheet
Executive Summary
U.S. Supreme Court justices focused their questioning during Nov. 3 oral arguments in the case of Wyeth v. Levine on the specific risk-benefit trade-off for the drug in question, but also addressed broader principles of FDA policy